Investor Presentaiton

Biosimilars: ☐ ☐ ☐ Biosimilars and Vaccines - The Next Big Opportunity Strong pipeline: 17 biosimilars and 2 novel products Strong IP position either through own patent or non-infringing processes. 120 experienced scientists dedicated to Biosimilars programme End to end product development and mfg. to be done in-house at the dedicated facility Product G-CSF Multiple Sclerosis Oncology/Nephrology Nephrology Osteoporosis Mktg. Process Indication Cloning Devp. Pre-Clinical Regulatory Clinical Devp. Permission Devp. Authori- sation Oncology Peg G-CSF Oncology IFN a-2b Infectious diseases Peg IFN a-2b Infectious diseases IFN B 1b ΙΕΡΟ Prod 1 Teriparatide Prod 2 Prod 3 MAB 1 Oncology/RA MAB 2 Inflammation MAB 3 Oncology MAB 4 Oncology Prod 4 AMI Prod 5 Fertility Prod 6 Fertility MAB 5 Rabies PEG-EPO Nephrology Diabetes Rheumatoid Arthritis Vaccines: Acquired Etna Biotech, Italy, engaged in vaccine research and development State-of-the-art Vaccine Technology Center under construction Developed high quality vaccine for H1N1 in-house 1st Indian co. to launch H1N1 vaccine Several other vaccines under different stages of development 20 20

View entire presentation